One type of cancer therapy takes blood cells from a person, changes them in a lab, then
gives the cells back to the person. In this study, researchers are using an anti-CD22 gene, a
virus, and an immune receptor to change the cells.
To see if giving anti-CD22 Chimeric Antigen Receptor (CAR) cells to young people with
certain cancers is safe and effective.
People ages 1-30 with a leukemia or lymphoma that has not been cured by standard therapy.
Participants will be screened to ensure their cancer cells express the CD22 protein.
They will also have medical history, physical exam, blood and urine tests, heart tests,
scans, and x-rays. They may give spinal fluid or have bone marrow tests.
Participants may have eye and neurologic exams.
Participants will get a central venous catheter or a catheter in a large vein.
Participants will have white blood cells removed. Blood is removed through a needle in
an arm. White blood cells are removed. The rest of the blood is returned by needle in
the other arm.
The cells will be changed in a laboratory.
Participants will get two IV chemotherapy drugs over 4 days. Some will stay in the
hospital for this.
All participants will be in the hospital to get anti-CD22 CAR cells through IV. They
will stay until any bad side effects are gone.
Participants will have many blood tests. They may repeat some screening exams.
Participants will have monthly visits for 2-3 months, then every 3-6 months. They may
repeat some screening exams.
Participants will have follow-up for 15 years.
Adoptive cellular therapy with T cells genetically modified using viral-based vectors to
express chimeric antigen receptors targeting the CD19 molecule have demonstrated
dramatic clinical responses in patients with acute lymphoblastic leukemia (ALL).
However, not all patients respond and CD19-negative escape has been observed following
CD19 CAR therapy, as well as anti-CD19/CD3 bispecific antibody therapy. Thus, additional
targets are needed.
CD22 is a B-lineage-restricted, transmembrane phosphoglycoprotein of the Ig superfamily
that is widely expressed on B-cell malignancies including 96% to 100% of pediatric
Bprecursor ALL. Therefore, CD22 represents a promising target. Encouraging responses
targeting CD22 with an antibody based immunoconjugate have been seen in patients,
including children, with recurrent and refractory ALL. This will be the first in human
testing of anti-CD22 CAR adoptive cell therapy.
To determine the feasibility of producing anti-CD22 CAR cells meeting established
release criteria. Complete
To assess the safety of administering escalating doses of anti-CD22-CAR engineered T
cells in children and young adults with recurrent or refractory CD22- expressing B cell
malignancies following a cyclophosphamide/fludarabine preparative regimen.
Patients 3-30 years of age, at least 14.5 kg, with CD22-expressing B-cell malignancies that
have recurred after or not responded to one or more standard regimens and deemed incurable by
standard therapy. Patients with a history of allogeneic hematopoietic transplantation (SCT)
who meet all eligibility criteria are eligible to participate. Patients previously treated
with anti-CD19 CAR engineered T cells are also eligible.
PBMC will be obtained by leukapheresis, CD3+ cells enriched and cultured in the presence
of anti-CD3/-CD28 beads followed by lentiviral vector supernatant containing the
anti-CD22 (M971BBz) CAR.
On Day -4 (cell infusion is Day 0), patients will begin induction chemotherapy
comprising fludarabine 25 mg/m2 on Days -4, -3 and -2 and cyclophosphamide 900 mg/m2 on
The CD22-CAR cells will be infused on Day 0, with up to a 72h delay allowed for infusion
of fresh cells or a 7 day delay if cells are cryopreserved, if needed for resolution of
clinical toxicities, to generate adequate cell numbers, or to facilitate scheduling.
A phase I cell dose escalation scheme will be performed using 3 dose levels (3 x 10(5)
transduced T cells/kg; 1 x 10(6) transduced T cells/kg; and 3 x 10(6) transduced T
cells/kg;). If 2/6 patients have DLT at dose level 1, safety will be evaluated in a
de-escalated dose of 1 x 10(5) transduced T cells/kg (more or less 20%)). Once the
maximum tolerated dose (or highest level evaluated) is reached, enrollment into an
expansion cohort of a total of 58 patients at MTD in (32 with and 26 without previous
CD19 CAR T cells) will proceed to provide additional information regarding the
feasibility, safety and efficacy of this treatment. Patients who have previously
received CD19 CAR T cells will be evaluated separately from CAR-na(SqrRoot) ve patients
as response may be different in these two groups.
Patients will be monitored for toxicity, response and T cell persistence as well as
other biologic correlates.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.